LTC2041177I2 - Didelio giminingumo antikūnai prieš žmogaus IL-6 receptorių - Google Patents

Didelio giminingumo antikūnai prieš žmogaus IL-6 receptorių

Info

Publication number
LTC2041177I2
LTC2041177I2 LTPA2017038C LTPA2017038C LTC2041177I2 LT C2041177 I2 LTC2041177 I2 LT C2041177I2 LT PA2017038 C LTPA2017038 C LT PA2017038C LT PA2017038 C LTPA2017038 C LT PA2017038C LT C2041177 I2 LTC2041177 I2 LT C2041177I2
Authority
LT
Lithuania
Prior art keywords
receptor
human
high affinity
affinity antibodies
cdr2
Prior art date
Application number
LTPA2017038C
Other languages
English (en)
Lithuanian (lt)
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38792460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC2041177(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of LTPA2017038I1 publication Critical patent/LTPA2017038I1/lt
Publication of LTC2041177I2 publication Critical patent/LTC2041177I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
LTPA2017038C 2006-06-02 2017-11-23 Didelio giminingumo antikūnai prieš žmogaus IL-6 receptorių LTC2041177I2 (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81066406P 2006-06-02 2006-06-02
US84323206P 2006-09-08 2006-09-08
PCT/US2007/013062 WO2007143168A2 (en) 2006-06-02 2007-06-01 High affinity antibodies to human il-6 receptor

Publications (2)

Publication Number Publication Date
LTPA2017038I1 LTPA2017038I1 (lt) 2017-12-11
LTC2041177I2 true LTC2041177I2 (lt) 2018-09-10

Family

ID=38792460

Family Applications (1)

Application Number Title Priority Date Filing Date
LTPA2017038C LTC2041177I2 (lt) 2006-06-02 2017-11-23 Didelio giminingumo antikūnai prieš žmogaus IL-6 receptorių

Country Status (33)

Country Link
US (10) US7582298B2 (enExample)
EP (2) EP2041177B1 (enExample)
JP (3) JP5307708B2 (enExample)
KR (1) KR101464502B1 (enExample)
CN (2) CN102585002A (enExample)
AT (1) ATE537190T1 (enExample)
AU (1) AU2007254831B2 (enExample)
BR (1) BRPI0712224B8 (enExample)
CA (1) CA2652976C (enExample)
CR (1) CR10462A (enExample)
CY (3) CY1112456T1 (enExample)
DK (2) DK2041177T3 (enExample)
ES (2) ES2398076T3 (enExample)
GT (1) GT200800272A (enExample)
HR (2) HRP20120175T1 (enExample)
HU (1) HUS1700050I1 (enExample)
IL (1) IL195393A (enExample)
LT (1) LTC2041177I2 (enExample)
LU (1) LUC00050I2 (enExample)
ME (1) ME00519B (enExample)
MX (1) MX2008014804A (enExample)
MY (2) MY159787A (enExample)
NL (1) NL300911I2 (enExample)
NO (2) NO340778B1 (enExample)
NZ (2) NZ573557A (enExample)
PL (2) PL2374818T3 (enExample)
PT (2) PT2374818E (enExample)
RS (2) RS52176B (enExample)
RU (1) RU2433138C2 (enExample)
SI (2) SI2041177T1 (enExample)
SV (1) SV2008003113A (enExample)
TN (1) TNSN08502A1 (enExample)
WO (1) WO2007143168A2 (enExample)

Families Citing this family (378)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CN101537180B (zh) 2002-07-18 2016-02-10 莫鲁斯有限公司 抗体混合物的重组生产
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2007046489A1 (ja) 2005-10-21 2007-04-26 Chugai Seiyaku Kabushiki Kaisha 心疾患治療剤
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
US9260516B2 (en) 2006-04-07 2016-02-16 Osaka University Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
SI2041177T1 (sl) 2006-06-02 2012-03-30 Regeneron Pharma Visoko afinitetna protitelesa za humani IL receptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
JP2010510796A (ja) * 2006-11-30 2010-04-08 アストラゼネカ アクチボラグ インターロイキン−６とインターロイキン−６受容体との複合体に特異的な抗体
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
RU2450829C2 (ru) 2007-01-23 2012-05-20 Синсу Юниверсити Ингибитор хронического отторжения
MX343879B (es) * 2007-05-21 2016-11-25 Alderbio Holdings Llc Metodo de humanizacion de anticuerpo de conejo novedoso y anticuerpos de conejo humanizados.
US8404235B2 (en) * 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
PL3187506T3 (pl) 2007-05-21 2019-09-30 Alderbio Holdings Llc Przeciwciała przeciwko IL-6 i ich zastosowanie
ES2517872T3 (es) 2007-08-10 2014-11-04 Regeneron Pharmaceuticals, Inc. Anticuerpos humanos de alta afinidad para el factor de crecimiento nervioso humano
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
CA3139492C (en) 2007-09-26 2024-04-30 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
TWI578998B (zh) 2007-09-26 2017-04-21 中外製藥股份有限公司 抗ｉｌ－６受體的抗體
EP3056513A1 (en) 2008-04-11 2016-08-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
MX2010012031A (es) 2008-05-13 2011-01-20 Novimmune Sa Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos.
EP2288623B1 (en) * 2008-05-23 2013-07-10 Ablexis, LLC Method of generating single vl domain antibodies in transgenic animals
TWI528973B (zh) * 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
DK3456190T3 (da) 2008-06-27 2022-02-14 Merus Nv Antistofproducerende transgent murint dyr
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
AU2012200724B8 (en) * 2008-09-26 2014-09-11 Chugai Seiyaku Kabushiki Kaisha Improved antibody molecules
CN102245207B (zh) 2008-11-13 2015-11-25 费塔制药股份有限公司 人源化抗il-6抗体
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
KR101595808B1 (ko) * 2009-02-24 2016-02-19 에스바테크 - 어 노바티스 컴파니 엘엘씨 세포-표면 항원의 면역결합제를 동정하는 방법
SG10201408247SA (en) * 2009-02-24 2015-02-27 Esbatech Alcon Biomed Res Unit Methods for identifying immunobinders of cell-surface antigens
EP3674317B1 (en) 2009-03-19 2024-12-11 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
RU2565809C2 (ru) * 2009-03-19 2015-10-20 Чугаи Сейяку Кабусики Кайся Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
AU2010233658B2 (en) 2009-04-10 2013-11-28 Ablynx Nv Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
EP2417162A2 (en) * 2009-04-10 2012-02-15 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
DK2792236T4 (da) 2009-07-08 2023-05-15 Kymab Ltd Dyremodeller og terapeutiske molekyler
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
ES2981683T3 (es) * 2009-10-26 2024-10-10 Hoffmann La Roche Procedimiento para la producción de una inmunoglobulina glucosilada
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
US20120294852A1 (en) 2009-11-24 2012-11-22 Smith Jeffrey T L Antagonists of il-6 to raise albumin and/or lower crp
SG181477A1 (en) 2009-12-10 2012-07-30 Regeneron Pharma Mice that make heavy chain antibodies
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
NZ631363A (en) 2010-02-08 2016-05-27 Regeneron Pharma Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9273316B2 (en) * 2010-05-21 2016-03-01 Peptimed, Inc. Reagents and methods for treating cancer
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
EP4115906A1 (en) 2010-05-28 2023-01-11 Chugai Seiyaku Kabushiki Kaisha Antitumor t cell response enhancer
BR112012032182A2 (pt) 2010-06-16 2016-10-25 Trellis Bioscience Inc anticorpos humanos de alta afinidade para proteína gb de citomegalovírus (cmv) humano.
SG10201912639SA (en) 2010-08-02 2020-02-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
US9533039B2 (en) 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
JO3756B1 (ar) * 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
WO2012071561A2 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
TWI761912B (zh) 2010-11-30 2022-04-21 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
WO2012098238A1 (en) 2011-01-21 2012-07-26 Novimmune S.A. Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
SI2668212T1 (en) 2011-01-28 2018-08-31 Sanofi Biotechnology, Human antibodies against PCSK9 for use in the treatment processes of certain groups of subjects
SMT201900581T1 (it) 2011-02-25 2019-11-13 Regeneron Pharma Topi adam6
BR112013021863A2 (pt) 2011-03-03 2016-11-22 Apexigen Inc anticorpos anti-receptor il-6 e métodos de uso
US11028149B2 (en) 2011-04-01 2021-06-08 Chugai Seiyaku Kabushiki Kaisha Recombinant polypeptide production method
EP2631654B1 (en) 2011-05-12 2015-04-15 Regeneron Pharmaceuticals, Inc. Neuropeptide release assay for sodium channels
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
DK2739740T3 (da) 2011-08-05 2019-12-09 Regeneron Pharma Universelle, humaniserede letkæde-mus
BR112014006394A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
EP2747782B1 (en) 2011-09-23 2018-01-17 Ablynx NV Prolonged inhibition of interleukin-6 mediated signaling
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
EA201791393A3 (ru) 2011-09-30 2018-03-30 Ридженерон Фармасьютикалз, Инк. Антитела к erbb3 и их применение
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
HRP20180299T1 (hr) * 2011-10-11 2018-04-20 Sanofi Biotechnology Pripravci za liječenje reumatoidnog artritisa i postupci za njihovo korištenje
CN108200885B (zh) 2011-10-17 2021-12-14 瑞泽恩制药公司 受限制的免疫球蛋白重链基因座
WO2013059548A1 (en) 2011-10-19 2013-04-25 Sanofi Compositions and methods for treating cancer using jak2 inhibitor
CN103059137A (zh) * 2011-10-21 2013-04-24 神州细胞工程有限公司 抗hIL6R高亲和力抗体的制备及应用
WO2013059426A1 (en) * 2011-10-21 2013-04-25 The Regents Of The University Of California Human endogenous retrovirus peptides, antibodies to the peptides, and methods of use thereof
DK2663575T3 (en) 2011-10-28 2014-12-15 Regeneron Pharma HUMANIZED IL-6 and IL-6 receptor
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
PL2780368T3 (pl) 2011-11-14 2018-06-29 Regeneron Pharmaceuticals, Inc. Kompozycje i sposoby do zwiększania masy mięśni i siły mięśni poprzez swoiste antaganizowanie GDF8 i/lub aktywiny A
DK2782598T3 (da) 2011-11-23 2020-08-10 In3Bio Ltd Rekombinante proteiner og terapeutiske anvendelser deraf
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US9706759B2 (en) 2011-12-20 2017-07-18 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
US9150648B2 (en) 2012-01-31 2015-10-06 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof
US9371383B2 (en) 2012-01-31 2016-06-21 Regeneron Pharmaceuticals, Inc. Anti-ASIC1 antibodies and uses thereof
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
MX2014010527A (es) 2012-03-02 2014-10-14 Regeneron Pharma Anticuerpos humanos para toxinas de clostridium difficile.
KR20140136462A (ko) 2012-03-06 2014-11-28 리제너론 파마슈티칼스 인코포레이티드 공통 경쇄 마우스
NZ629077A (en) 2012-03-16 2015-12-24 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
WO2013138681A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
PT2825036T (pt) 2012-03-16 2018-07-26 Regeneron Pharma Anticorpos de cadeia leve manipulados em histidina e roedores geneticamente modificados para gerar os mesmos
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
TWI619729B (zh) 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途
RS59263B1 (sr) 2012-04-20 2019-10-31 Merus Nv Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
LT3597037T (lt) 2012-06-12 2021-06-10 Regeneron Pharmaceuticals, Inc. Humanizuoti gyvūnai, išskyrus žmones, su apribotu imunoglobulino sunkiosios grandinės lokusu
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
ES2701093T3 (es) 2012-08-21 2019-02-20 Sanofi Biotechnology Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R
JO3462B1 (ar) 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
NZ731864A (en) 2012-09-07 2022-07-01 Regeneron Pharma Methods for treating atopic dermatitis by administering an il-4r antagonist
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
KR20150084007A (ko) 2012-11-13 2015-07-21 리제너론 파아마슈티컬스, 인크. 항-프로키네티신 수용체 (ｐｒｏｋｒ) 항체 및 이의 용도
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
DK2840892T3 (en) 2013-02-20 2018-07-23 Regeneron Pharma Non-human animals with modified heavy chain immunoglobulin sequences
CN108611369B (zh) 2013-03-13 2022-08-26 瑞泽恩制药公司 表达限制的免疫球蛋白轻链库的小鼠
CA2903696A1 (en) 2013-03-13 2014-10-02 Regeneron Pharmaceuticals, Inc. Common light chain mouse
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
CA2902572A1 (en) 2013-03-14 2014-10-02 Regeneron Pharmaceuticals, Inc. Human antibodies to nav1.7
MX369574B (es) 2013-03-14 2019-11-13 Regeneron Pharma Anticuerpos humanos contra grem1.
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
SI3010539T1 (sl) 2013-06-21 2019-11-29 Regeneron Pharma Postopki za zdravljenje nazalne polipoze z administriranjem antagonista IL-4R
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
WO2015027154A2 (en) 2013-08-23 2015-02-26 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
LT3046412T (lt) 2013-09-18 2019-07-25 Regeneron Pharmaceuticals, Inc. Histidino pakeitimus lengvoje grandinėje turintys antikūnai ir genetiškai modifikuoti gyvūnai, išskyrus žmogų, išvesti jų gamybai
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
CA2925723A1 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
MX2016005686A (es) 2013-10-31 2016-08-11 Regeneron Pharma Ensayo de union competitiva al ligando para detectar anticuerpos neutralizantes.
EA201691027A1 (ru) 2013-11-20 2016-12-30 Ридженерон Фармасьютикалз, Инк. Модуляторы aplnr и их применение
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
WO2015095511A2 (en) * 2013-12-20 2015-06-25 The Scripps Research Institute Functional antibodies that modulate cell death and related methods
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
WO2015116852A1 (en) 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating rheumatoid arthritis by administering an il-6r antibody
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
EA035809B1 (ru) 2014-03-11 2020-08-14 Регенерон Фармасьютикалс, Инк. АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
KR102601491B1 (ko) 2014-03-21 2023-11-13 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
WO2015143406A2 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
EA201790377A1 (ru) 2014-09-16 2017-08-31 Регенерон Фармасьютикалз, Инк. Антитела к глюкагону и их применения
US9840557B2 (en) 2014-09-23 2017-12-12 Regeneron Pharmaceuticals, Inc. Anti-IL-25 antibodies and uses thereof
US10118967B2 (en) 2014-10-21 2018-11-06 Ablynx N.V. Methods for treating rheumatoid arthritis by administering IL-6 receptor antibodies
MX2017006286A (es) 2014-11-14 2018-01-23 Sanofi Biotechnology Metodos para tratar sinusitis cronica con polipos nasales por administracion de un antagonista de il-4r.
RS60739B1 (sr) 2014-11-17 2020-09-30 Regeneron Pharma Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela
EP3226899A4 (en) * 2014-12-02 2018-09-05 Regeneron Pharmaceuticals, Inc. Methods for treating dry eye disease by administering an il-6r antagonist
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
KR20180095740A (ko) 2015-02-27 2018-08-27 추가이 세이야쿠 가부시키가이샤 Il-6 관련 질환 치료용 조성물
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
EP3283519A1 (en) 2015-04-15 2018-02-21 Regeneron Pharmaceuticals, Inc. Methods of increasing strength and functionality with gdf8 inhibitors
JP2016208934A (ja) * 2015-05-12 2016-12-15 学校法人日本大学 抗イヌインターロイキン−６受容体モノクローナル抗体又は抗体フラグメント及びその利用
JP6875683B2 (ja) 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
US11174317B2 (en) 2015-06-04 2021-11-16 National Center Of Neurology And Psychiatry Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient
ES2971045T3 (es) 2015-07-06 2024-06-03 Regeneron Pharma Moléculas multiespecíficas de unión a antígeno y usos de las mismas
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR20180034672A (ko) 2015-08-18 2018-04-04 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
CA3009161A1 (en) 2015-12-22 2017-06-29 Regeneron Pharmaceuticals, Inc. Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
MX2018007781A (es) 2015-12-28 2018-09-05 Chugai Pharmaceutical Co Ltd Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
IL260526B2 (en) 2016-01-13 2023-10-01 Regeneron Pharma Rodents having an engineered heavy chain diversity region
US20170247436A1 (en) 2016-02-16 2017-08-31 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene
JP7166925B2 (ja) 2016-03-07 2022-11-08 サノフィ・バイオテクノロジー 関節リウマチを処置するための組成物及び方法
EP3216461A1 (en) 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis
HRP20212028T1 (hr) 2016-04-08 2022-04-01 Regeneron Pharmaceuticals, Inc. Postupci za liječenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3
SG10202010156XA (en) 2016-04-20 2020-11-27 Regeneron Pharma Compositions and methods for making antibodies based on use of an expression-enhancing locus
CN109195986B (zh) 2016-04-20 2023-01-03 瑞泽恩制药公司 基于使用表达增强性基因座来制备抗体的组合物和方法
WO2017190079A1 (en) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
TW202408578A (zh) 2016-05-13 2024-03-01 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
IL262888B1 (en) 2016-05-20 2025-10-01 Regeneron Pharma Methods for breaking immunological tolerance using multiple guide RNAs
WO2017201731A1 (en) * 2016-05-27 2017-11-30 Beijing Vdjbio Co., Ltd. Antibodies, composition and kits comprising same, and methods of use thereof
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
IL263273B2 (en) 2016-06-10 2025-10-01 Regeneron Pharma Antibodies against GITR and their uses
MY191668A (en) 2016-06-14 2022-07-06 Regeneron Pharma Anti-c5 antibodies and uses thereof
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
RU2656160C2 (ru) * 2016-08-17 2018-05-31 Закрытое Акционерное Общество "Биокад" Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
MX2019002344A (es) 2016-09-01 2019-09-06 Regeneron Pharma Metodos de prevenir o tratar la alergia administrando un antagonista de il-4r.
WO2018058001A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
WO2018058003A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-muc16 (mucin 16) antibodies
SG11201903344XA (en) 2016-11-04 2019-05-30 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain locus
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
JP7133551B2 (ja) 2016-11-17 2022-09-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ａｎｇｐｔｌ８抗体を用いて肥満を処置する方法
JP7174699B2 (ja) 2016-11-29 2022-11-17 レゲネロン ファーマシューティカルス，インコーポレーテッド Ｐｒｌｒ陽性乳癌の治療方法
AU2017366870B2 (en) 2016-11-29 2024-09-19 Regeneron Pharmaceuticals, Inc. A pharmaceutical composition for averting opioid addiction
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
BR112019011186A2 (pt) 2016-12-01 2019-10-08 Regeneron Pharmaceuticals, Inc. conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
US11352417B2 (en) 2016-12-22 2022-06-07 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
JP7167041B2 (ja) 2017-02-10 2022-11-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔイメージングのための放射標識抗ｌａｇ３抗体
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
MY198270A (en) 2017-06-01 2023-08-18 Regeneron Pharma Human Antibodies To Bet V 1 And Methods Of Use Thereof
KR102760654B1 (ko) 2017-06-07 2025-02-04 리제너론 파마슈티칼스 인코포레이티드 효소 내재화를 위한 조성물 및 방법
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
US20190048072A1 (en) 2017-06-22 2019-02-14 Novartis Ag USE OF IL-1beta BINDING ANTIBODIES
IL299348B2 (en) 2017-06-28 2025-05-01 Regeneron Pharma Antigen-binding proteins against human papillomavirus and methods of using them
AU2018298039B2 (en) 2017-07-06 2023-02-02 Regeneron Pharmaceuticals, Inc. Cell culture process for making a glycoprotein
TWI799432B (zh) 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
JP2021500856A (ja) * 2017-09-13 2021-01-14 江蘇恒瑞医薬股▲ふん▼有限公司 Ｉｌ−６ｒ抗体およびその抗原結合フラグメントならびに医薬としての使用
BR112020004977A2 (pt) 2017-09-29 2020-10-06 Regeneron Pharmaceuticals, Inc. moléculas de ligação de antígenos biespecíficas que ligam antígeno alvo de staphyocococcus e componente de complemento e usos dos mesmos
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
JP7315545B2 (ja) 2017-10-30 2023-07-26 サノフィ・バイオテクノロジー Ｉｌ－４ｒ拮抗薬の投与により喘息を処置または予防するための方法
MY203247A (en) 2017-11-30 2024-06-19 Regeneron Pharma Anti-trkb monoclonal antibodies and methods of use
SMT202500277T1 (it) 2017-12-05 2025-09-12 Regeneron Pharma Topi aventi una catena leggera lambda di immunoglobuline ingegnerizzata e loro usi
MA51147A (fr) 2017-12-13 2021-03-24 Regeneron Pharma Associations d'anticorps anti-c5 et utilisations associées
WO2019126194A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
KR20200100089A (ko) 2017-12-18 2020-08-25 리제너론 파마슈티칼스 인코포레이티드 렙틴 수용체 및/또는 gp130에 결합하는 이중 특이적 항원 결합 분자 및 이의 사용 방법
AU2018392334A1 (en) 2017-12-22 2020-05-28 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
IL275884B2 (en) 2018-01-26 2024-11-01 Regeneron Pharma Human antibodies to influenza hemagglutinin
SG11202005235WA (en) 2018-01-31 2020-07-29 Regeneron Pharma System and method for characterizing size and charge variant drug product impurities
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
MA51796A (fr) 2018-02-07 2020-12-16 Regeneron Pharma Procédés et compositions pour l'administration de protéines thérapeutiques
CN111771000A (zh) 2018-02-28 2020-10-13 瑞泽恩制药公司 用于鉴定病毒污染物的系统和方法
JP7579706B2 (ja) 2018-03-01 2024-11-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 体組成を変更するための方法
WO2019182901A1 (en) 2018-03-19 2019-09-26 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
WO2019190931A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Anti-pfrh5 antibodies and antigen-binding fragments thereof
IL278244B1 (en) 2018-04-30 2025-09-01 Regeneron Pharma Antibodies and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates and uses thereof
JP7590871B2 (ja) 2018-05-09 2024-11-27 レゲネロン ファーマシューティカルス，インコーポレーテッド 抗ｍｓｒ１抗体及びその使用方法
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
US12252544B2 (en) 2018-05-17 2025-03-18 Regeneron Pharmaceuticals, Inc. Anti-CD63 antibodies, conjugates, and uses thereof
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
US12068729B2 (en) 2018-06-19 2024-08-20 Regeneron Pharmaceuticals, Inc. Anti-factor XII/XIIa antibodies and uses thereof
US11548947B2 (en) 2018-06-21 2023-01-10 Regeneron Pharmaceuticals, Inc. Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
DK4324851T3 (da) 2018-07-19 2025-10-06 Regeneron Pharma Kimæriske antigenreceptorer med BCMA-specificitet og anvendelser deraf
KR20210043624A (ko) 2018-08-10 2021-04-21 리제너론 파아마슈티컬스, 인크. 무릎 및/또는 고관절 통증의 안전하고 효과적인 치료를 위한 약제학적 조성물
CN112888482B (zh) 2018-08-23 2024-06-25 里珍纳龙药品有限公司 抗Fcε-R1α(FCER1A)抗体，结合FCER1A和CD3的双特异性抗原结合分子及其用途
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
SG11202101674QA (en) 2018-08-29 2021-03-30 Regeneron Pharma Methods and compositions for treating subjects having rheumatoid arthritis
US11754569B2 (en) 2018-08-30 2023-09-12 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
KR20210082207A (ko) 2018-10-23 2021-07-02 리제너론 파아마슈티컬스, 인크. 항-npr1 항체 및 이의 용도
EP4257195A3 (en) * 2018-11-09 2024-01-03 University of Massachusetts Anti-cfae antibodies and methods of use
WO2020106814A1 (en) 2018-11-21 2020-05-28 Regeneron Pharmaceuticals, Inc. Anti-staphylococcus antibodies and uses thereof
MA54540A (fr) 2018-12-19 2021-10-27 Regeneron Pharma Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
WO2020132024A1 (en) 2018-12-19 2020-06-25 Regeneron Pharmaceuticals, Inc. Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
US20220025036A1 (en) 2018-12-21 2022-01-27 Novartis Ag Use of il-1beta binding antibodies
WO2020146239A1 (en) * 2019-01-07 2020-07-16 Celledit Llc Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy
EP3857236A1 (en) 2019-01-16 2021-08-04 Regeneron Pharmaceuticals, Inc. Methods for identifying free thiols in proteins
TW202521583A (zh) 2019-01-31 2025-06-01 法商賽諾菲生物技術公司 用於治療幼年原發性關節炎之組成物及方法
CN113412121A (zh) 2019-02-12 2021-09-17 瑞泽恩制药公司 使用双特异性抗体结合补体和靶抗原的组合物和方法
AU2020224136C1 (en) 2019-02-21 2025-09-25 Regeneron Pharmaceuticals, Inc. Methods of treating ocular cancer using anti-MET antibodies and bispecific antigen binding molecules that bind MET
WO2020178193A1 (en) 2019-03-01 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of sarcoidosis
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
PH12021552300A1 (en) 2019-03-22 2022-07-04 Regeneron Pharma EGFR x CD28 MULTISPECIFIC ANTIBODIES
MX2021012335A (es) 2019-04-10 2021-11-12 Regeneron Pharma Anticuerpos humanos que se unen a ret y metodos de uso de los mismos.
KR20220088829A (ko) 2019-04-24 2022-06-28 사노피 바이오테크놀로지 류마티스 관절염의 진단 및 치료 방법
CA3138306A1 (en) 2019-05-01 2020-11-05 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-33 antagonist
KR20220007586A (ko) 2019-05-13 2022-01-18 리제너론 파마슈티칼스 인코포레이티드 개선된 경쟁적 리간드 결합 검정
AU2020288561A1 (en) 2019-06-04 2021-12-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating pain in subjects with rheumatoid arthritis
MX2021014893A (es) 2019-06-05 2022-03-11 Regeneron Pharma Animales no humanos que tienen un repertorio de cadena ligera lambda limitado expresado a partir del locus kappa y usos de estos.
CN113966343A (zh) 2019-06-11 2022-01-21 瑞泽恩制药公司 结合PcrV的抗PcrV抗体、包含抗PcrV抗体的组合物及其使用方法
US20220275088A1 (en) * 2019-06-14 2022-09-01 Dana-Farber Cancer Institute, Inc. Antibodies against pd-1 and methods of use thereof
CA3141927A1 (en) * 2019-06-14 2020-12-17 Dana-Farber Cancer Institute, Inc. Antibodies against pd-1 and methods of use thereof
CN114375205A (zh) 2019-06-20 2022-04-19 武田药品工业株式会社 用基于病毒的基因疗法进行治疗的方法
EP3999114A1 (en) 2019-07-16 2022-05-25 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
MX2022000896A (es) 2019-07-24 2022-02-14 Regeneron Pharma Receptores de antigenos quimericos con especificidad por mage-a4 y usos de los mismos.
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
IL317159A (en) 2019-09-24 2025-01-01 Regeneron Pharma Systems and methods for use in chromatography and regeneration
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
JP7611908B2 (ja) 2019-10-28 2025-01-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗血球凝集素抗体およびその使用方法
CN114760986A (zh) 2019-11-25 2022-07-15 里珍纳龙药品有限公司 使用非水性乳液的持续释放调配物
CA3160521A1 (en) 2019-12-06 2021-06-10 Sanofi Biotechnology Methods for treating copd by administering an il-33 antagonist
JP7693672B2 (ja) 2019-12-06 2025-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法
CN115151568A (zh) 2019-12-23 2022-10-04 赛诺菲生物技术公司 用于通过施用il-33拮抗剂和/或il-4r拮抗剂以治疗或预防过敏性哮喘的方法
MX2022008973A (es) 2020-01-21 2022-08-11 Regeneron Pharma Metodos de desglicosilacion para electroforesis de proteinas glicosiladas.
EP4093767A1 (en) 2020-01-22 2022-11-30 H. Lee Moffitt Cancer Center & Research Institute, Inc. Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor
CN115427457A (zh) 2020-02-10 2022-12-02 瑞泽恩制药公司 抗tmprss2抗体和抗原结合片段
WO2021163170A1 (en) 2020-02-11 2021-08-19 Regeneron Pharmaceuticals, Inc. Anti-acvr1 antibodies and uses thereof
AU2021228225A1 (en) 2020-02-28 2022-09-01 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind HER2, and methods of use thereof
IL296043A (en) 2020-03-06 2022-10-01 Regeneron Pharma Anti-gitro antibodies and their uses
KR102831970B1 (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
MX2022013894A (es) * 2020-05-06 2022-11-30 Sorrento Therapeutics Inc Anticuerpos neutralizantes que se unen a la proteina s del sars-cov-2.
WO2021231366A1 (en) 2020-05-12 2021-11-18 Regeneron Pharmaceuticals, Inc. Anti-glp1r antagonist antibodies and methods of use thereof
EP4153626A4 (en) * 2020-05-18 2024-09-11 Biosion, Inc. IL6R-BINDING ANTIBODIES AND USES THEREOF
US20240043504A1 (en) 2020-05-26 2024-02-08 Regeneron Pharmaceuticals, Inc. Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
US20230174657A1 (en) 2020-05-26 2023-06-08 Sanofi Biotechnology Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
WO2021240436A1 (en) 2020-05-29 2021-12-02 Sanofi Biotechnology Compositions and methods for treating noninflammatory pain in subjects with rheumatoid arthritis
EP4164673A4 (en) * 2020-06-16 2024-12-04 HiFiBiO (HK) Limited METHODS AND COMPOSITIONS RELATED TO NEUTRALISING ANTIBODIES AGAINST HUMAN CORONAVIRUS
WO2022032139A1 (en) * 2020-08-07 2022-02-10 Sorrento Therapeutics, Inc. Neutralizing antibodies that bind the sars-cov-2 s protein
AU2021327238A1 (en) 2020-08-20 2023-04-27 Regeneron Pharmaceuticals, Inc. Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists
US20220064270A1 (en) 2020-08-26 2022-03-03 Regeneron Pharmaceuticals, Inc. Method of treating an allergy with allergen-specific monoclonal antibodies
WO2022047108A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
JP2023543152A (ja) 2020-09-18 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用
CA3194111A1 (en) 2020-10-05 2022-04-14 Christine XU Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
CA3190569A1 (en) 2020-10-22 2022-04-28 Christopher Daly Anti-fgfr2 antibodies and methods of use thereof
US12239687B2 (en) 2020-11-25 2025-03-04 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
KR20230121854A (ko) 2020-12-17 2023-08-21 리제너론 파아마슈티컬스, 인크. 단백질-캡슐화 마이크로겔의 제작
IL303542A (en) 2020-12-18 2023-08-01 Regeneron Pharma Immunoglobulin proteins that bind to NPR1 agonists
ES3025508T3 (en) 2020-12-23 2025-06-09 Regeneron Pharma Nucleic acids encoding anchor modified antibodies and uses thereof
CA3202197A1 (en) 2021-01-20 2022-07-28 Reginald Smith Methods of improving protein titer in cell culture
EP4302098A1 (en) 2021-03-03 2024-01-10 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
WO2022187626A1 (en) 2021-03-05 2022-09-09 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
EP4315344A1 (en) 2021-03-26 2024-02-07 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
BR112023021256A2 (pt) 2021-04-20 2023-12-12 Regeneron Pharma Anticorpos humanos para artemina e métodos de uso dos mesmos
IL308231A (en) 2021-05-04 2024-01-01 Regeneron Pharma MAGE-44-specific chimeric antigen receptors and their uses
JP2024517844A (ja) 2021-05-04 2024-04-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多重特異性ｆｇｆ２１受容体アゴニスト及びそれらの使用
MX2023013248A (es) 2021-05-11 2024-01-29 Regeneron Pharma Anticuerpos anti-tmprss6 y sus usos.
IL308695A (en) 2021-06-01 2024-01-01 Servier Lab Anti-NKG2A antibodies and compositions
CA3220848A1 (en) 2021-06-01 2022-12-08 Timothy Riehlman Microchip capillary electrophoresis assays and reagents
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
CA3226042A1 (en) 2021-07-05 2023-01-12 Regeneron Pharmaceuticals, Inc. Utilization of antibodies to shape antibody responses to an antigen
TW202321292A (zh) 2021-07-14 2023-06-01 美商再生元醫藥公司 抗sars-cov-2-棘醣蛋白抗體及抗原結合片段
IL310362A (en) 2021-07-26 2024-03-01 Sanofi Biotechnology Methods for the treatment of chronic spontaneous urticaria by administration of an IL-4R antagonist
AR127006A1 (es) 2021-09-08 2023-12-06 Regeneron Pharma UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
US20230090912A1 (en) 2021-09-20 2023-03-23 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
IL311248A (en) 2021-10-07 2024-05-01 Regeneron Pharma PH meter calibration and repair
US20230116199A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
CN119137149A (zh) 2021-10-20 2024-12-13 赛诺菲生物技术公司 用于通过施用il-4r拮抗剂来治疗结节性痒疹的方法
US12304969B2 (en) 2021-10-22 2025-05-20 Regeneron Pharmaceuticals, Inc. Factor XI A2 domain-binding antibodies and methods of use thereof
KR20240097864A (ko) 2021-10-26 2024-06-27 리제너론 파마슈티칼스 인코포레이티드 상이한 온도에서 실험실 용수를 생성하고 실험실 용수를 분배하는 시스템 및 방법
US20250011408A1 (en) 2021-11-19 2025-01-09 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
US20230250170A1 (en) 2021-12-06 2023-08-10 Regeneron Pharmaceuticals, Inc. Antagonist anti-npr1 antibodies and methods of use thereof
EP4493921A1 (en) 2022-03-18 2025-01-22 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
WO2023196903A1 (en) 2022-04-06 2023-10-12 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
WO2023212586A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Methods for selecting patients for treatment with an ngf antagonist
KR20250011926A (ko) 2022-05-18 2025-01-22 리제너론 파마슈티칼스 인코포레이티드 Cd38 및 4-1bb에 결합하는 다중특이적 항원 결합 분자, 및 이의 용도
EP4554977A1 (en) 2022-07-12 2025-05-21 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
JP2025528456A (ja) 2022-08-29 2025-08-28 サノフィ・バイオテクノロジー Ｉｌ－４ｒアンタゴニストの投与による慢性誘発性寒冷蕁麻疹の治療方法
AU2023376911A1 (en) 2022-11-07 2025-05-15 Regeneron Pharmaceuticals, Inc. Factor xi catalytic domain-binding antibodies and methods of use thereof
US20240190978A1 (en) 2022-11-15 2024-06-13 CSBioAsset LLC Compositions and methods for immunomodulatory bifunctional fusion molecules
WO2024130165A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome
KR20250124178A (ko) 2022-12-16 2025-08-19 리제너론 파아마슈티컬스, 인크. 크로마토그래피 칼럼의 무결성을 평가하기 위한 방법 및 시스템
AU2024207469A1 (en) 2023-01-13 2025-08-28 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
US20240248097A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
TW202445135A (zh) 2023-01-25 2024-11-16 美商再生元醫藥公司 液態蛋白質組成物穩定性之建模方法
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
CN120677178A (zh) 2023-02-13 2025-09-19 瑞泽恩制药公司 用抗人cacng1抗体治疗肌肉相关病症
US20240299601A1 (en) 2023-02-17 2024-09-12 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
WO2024197119A1 (en) 2023-03-22 2024-09-26 Sanofi Biotechnology Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
AU2024265540A1 (en) 2023-05-01 2025-10-30 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
AU2024265507A1 (en) 2023-05-02 2025-10-30 Regeneron Pharmaceuticals, Inc. Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
WO2024259206A1 (en) 2023-06-16 2024-12-19 Regeneron Pharmaceuticals, Inc. Cd40 x cd40 bispecific antigen-binding molecules and uses thereof
WO2025014533A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Anti-human cacng1 antibody-drug conjugates and uses thereof
TW202519559A (zh) 2023-07-10 2025-05-16 美商再生元醫藥公司 雙特異性PD-L1xCD28抗體及其使用方法
CN119285767B (zh) * 2023-07-10 2025-11-18 东莞市朋志生物科技有限公司 抗白介素-6抗体、检测白介素-6的试剂和试剂盒
TW202519547A (zh) 2023-07-10 2025-05-16 美商再生元醫藥公司 雙特異性PD-L1x4-1BB抗體及其使用方法
WO2025019789A1 (en) 2023-07-19 2025-01-23 Regeneron Pharmaceuticals, Inc. ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF
WO2025054406A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2025064403A2 (en) 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
US20250109905A1 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025149845A1 (en) 2024-01-12 2025-07-17 Sanofi Biotechnology Treatment of subjects with polymyalgia rheumatica who have been receiving a steroid
WO2025149846A1 (en) 2024-01-12 2025-07-17 Sanofi Biotechnology Compositions and methods for treating frail subjects with polymyalgia rheumatica by administering an il-6r antagonist
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
WO2025221640A1 (en) 2024-04-15 2025-10-23 Sanofi Biotechnology Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
CN119775414B (zh) * 2025-03-12 2025-06-06 武汉伊莱瑞特生物科技股份有限公司 抗猴白介素-6单克隆抗体、酶联免疫检测试剂盒及其应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
CA1341152C (en) * 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5216128A (en) 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
CA2021594C (en) 1989-07-20 2002-01-08 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JPH05227970A (ja) * 1992-02-19 1993-09-07 Chugai Pharmaceut Co Ltd ヒトインターロイキン−６受容体に対する再構成ヒト抗体
KR100249937B1 (ko) 1991-04-25 2000-04-01 나가야마 오사무 인간 인터루킨-6 수용체에 대한 재구성 인간 항체
FR2694767B1 (fr) 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
AU687763B2 (en) 1992-10-20 1998-03-05 Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service Interleukin-6 receptor antagonists
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU7967294A (en) * 1993-10-06 1995-05-01 Board Of Regents, The University Of Texas System A monoclonal anti-human il-6 receptor antibody
ATE552012T1 (de) 1994-10-07 2012-04-15 Chugai Pharmaceutical Co Ltd Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff
HU225392B1 (en) * 1994-10-21 2006-11-28 Chugai Pharmaceutical Co Ltd Use of an antibody againts interleukin-6-receptor for producing a pharmaceutical composition for treating anemia and cachexia caused by il-6 production
US6086874A (en) * 1994-12-29 2000-07-11 Chugai Seiyaku Kabushiki Kaisha Antitumor agent effect enhancer containing IL-6 antagonist
ATE330629T1 (de) 1995-02-13 2006-07-15 Chugai Pharmaceutical Co Ltd Inhibitor des muskelproteinabbaus enthaltend einen il-6 rezeptor antikörper
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5785965A (en) 1996-05-15 1998-07-28 The Board Of Trustees Of The Leland Stanford Junior Univ. VEGF gene transfer into endothelial cells for vascular prosthesis
ATE326238T1 (de) * 1996-06-27 2006-06-15 Chugai Pharmaceutical Co Ltd Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoff-senfgasen verwendet werden kann
KR20040024561A (ko) 1997-08-15 2004-03-20 츄가이 세이야꾸 가부시키가이샤 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는전신성 홍반성 낭창의 예방 및/또는 치료제
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
JP4124573B2 (ja) 1998-03-17 2008-07-23 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する炎症性腸疾患の予防又は治療剤
PT1108435E (pt) 1998-08-24 2007-04-30 Chugai Pharmaceutical Co Ltd Agentes preventivos ou terapêuticos para pancreatite contendo antagonistas da il-6 como ingrediente activo
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
ES2644275T3 (es) 2000-08-11 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen anticuerpos
AU1091802A (en) 2000-10-20 2002-04-29 Chugai Pharmaceutical Co Ltd Degraded agonist antibody
AU1095202A (en) * 2000-10-25 2002-05-06 Chugai Pharmaceutical Co Ltd Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
JP4889187B2 (ja) * 2000-10-27 2012-03-07 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
JP3792698B2 (ja) 2002-02-14 2006-07-05 中外製薬株式会社 抗体含有溶液製剤
US20060078531A1 (en) * 2004-10-12 2006-04-13 Osemwota Sota Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
US20060078533A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US20060275294A1 (en) * 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
US20060078532A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
KR20050058486A (ko) * 2002-08-30 2005-06-16 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 인간형 항인간 인터루킨-6 항체 및 항체 단편
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP1673396A1 (en) 2003-09-22 2006-06-28 BioVation GmbH & Co.KG. Use of antibodies for reducing the biological effectiveness of il-6
US8617550B2 (en) * 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
WO2005080429A2 (en) * 2004-02-11 2005-09-01 Warner-Lambert Company Llc Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
US20070036788A1 (en) * 2004-09-22 2007-02-15 Ahmed Sheriff Use of a compound for reducing the biological effectiveness of il-6
JPWO2006046661A1 (ja) 2004-10-28 2008-05-22 国立大学法人大阪大学 インターロイキン−６阻害剤
KR20070095949A (ko) * 2004-12-16 2007-10-01 제넨테크, 인크. 자가면역 장애의 치료 방법
JP2008528060A (ja) * 2005-01-27 2008-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ボツリヌス神経毒素を中和する治療的モノクローナル抗体
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
SI2041177T1 (sl) 2006-06-02 2012-03-30 Regeneron Pharma Visoko afinitetna protitelesa za humani IL receptor
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
RU2319351C1 (ru) * 2006-09-13 2008-03-20 Олег Иванович Квасенков Способ подготовки к хранению яблок свежих специального назначения
US20100129354A1 (en) 2006-10-27 2010-05-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
EP2666787B1 (en) 2007-05-31 2022-02-09 Genmab A/S STABLE IgG4 ANTIBODIES
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2009109584A1 (en) 2008-03-07 2009-09-11 Ferring International Center S. A. ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX

Also Published As

Publication number Publication date
IL195393A (en) 2013-07-31
EP2041177A2 (en) 2009-04-01
CY1112456T1 (el) 2015-12-09
US20140255995A1 (en) 2014-09-11
CN102585002A (zh) 2012-07-18
CY2017039I2 (el) 2018-04-04
WO2007143168A2 (en) 2007-12-13
HUS1700050I1 (hu) 2017-12-28
ME00519B (me) 2011-10-10
BRPI0712224B8 (pt) 2021-05-25
RS52643B (sr) 2013-06-28
CN101454345A (zh) 2009-06-10
MY147468A (en) 2012-12-14
GT200800272A (es) 2009-08-21
US20210009698A1 (en) 2021-01-14
NO2017060I1 (no) 2017-11-14
MY159787A (en) 2017-01-31
NZ587107A (en) 2012-05-25
HRP20130228T1 (hr) 2013-04-30
HRP20120175T1 (hr) 2012-03-31
SV2008003113A (es) 2009-10-27
JP5307708B2 (ja) 2013-10-02
PT2374818E (pt) 2013-02-13
CA2652976A1 (en) 2007-12-13
SI2041177T1 (sl) 2012-03-30
EP2374818A1 (en) 2011-10-12
PT2041177E (pt) 2012-03-05
NO20085309L (no) 2009-03-02
JP2009539349A (ja) 2009-11-19
JP2016026171A (ja) 2016-02-12
NO340778B1 (no) 2017-06-19
PL2041177T3 (pl) 2012-09-28
CY1113708T1 (el) 2016-06-22
RU2433138C2 (ru) 2011-11-10
EP2374818B1 (en) 2012-12-19
CA2652976C (en) 2015-08-11
CY2017039I1 (el) 2018-04-04
CR10462A (es) 2009-03-20
CN101454345B (zh) 2012-08-08
US20070280945A1 (en) 2007-12-06
US10584173B2 (en) 2020-03-10
LUC00050I2 (enExample) 2018-01-23
WO2007143168A3 (en) 2008-04-24
US20120003697A1 (en) 2012-01-05
DK2041177T3 (da) 2012-02-27
US20250206829A1 (en) 2025-06-26
US20230094591A1 (en) 2023-03-30
ATE537190T1 (de) 2011-12-15
DK2374818T3 (da) 2013-01-21
RU2008152443A (ru) 2010-07-20
LTPA2017038I1 (lt) 2017-12-11
US8043617B2 (en) 2011-10-25
AU2007254831B2 (en) 2012-03-22
NZ573557A (en) 2010-08-27
US7582298B2 (en) 2009-09-01
MX2008014804A (es) 2009-01-27
JP2013226143A (ja) 2013-11-07
LUC00050I1 (enExample) 2017-11-22
IL195393A0 (en) 2011-08-01
AU2007254831A1 (en) 2007-12-13
ES2377579T3 (es) 2012-03-29
ES2398076T3 (es) 2013-03-13
US20130157313A1 (en) 2013-06-20
NL300911I2 (nl) 2018-02-01
US20100316627A1 (en) 2010-12-16
EP2041177B1 (en) 2011-12-14
US20190256606A1 (en) 2019-08-22
BRPI0712224A2 (pt) 2012-01-17
JP6140777B2 (ja) 2017-05-31
KR20090024690A (ko) 2009-03-09
PL2374818T3 (pl) 2013-05-31
US8183014B2 (en) 2012-05-22
RS52176B (sr) 2012-08-31
BRPI0712224B1 (pt) 2020-11-17
US11370843B2 (en) 2022-06-28
US9884916B2 (en) 2018-02-06
TNSN08502A1 (en) 2010-04-14
JP5805703B2 (ja) 2015-11-04
KR101464502B1 (ko) 2014-12-01
SI2374818T1 (sl) 2013-03-29
US20160229916A1 (en) 2016-08-11

Similar Documents

Publication Publication Date Title
LTPA2017038I1 (lt) Didelio giminingumo antikūnai prieš žmogaus IL-6 receptorių
HRP20191462T1 (hr) Antitijela usmjerena protiv her-3 i njihove uporabe
NZ623706A (en) Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
NO20074867L (no) Antistoffer mot CCR5 og anvendelser derav
CO6160305A2 (es) Anticuerpos humanos de alta afinidad para el receptor de il-4 humano
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
NZ599497A (en) Humanized antibodies to amyloid beta
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
CY1118709T1 (el) Αντιγονικα πεπτιδια του παραγοντα διεγερσης αποικιων των κοκκινοκυτταρων (gm-csf) και αντισωματα για ton gm-csf
PE20110801A1 (es) Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
NZ592214A (en) Improved Interleukin-6 receptor antibody molecule
RU2531523C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
NZ599683A (en) Anti-ilt7 antibody
JP2017505125A5 (enExample)
NZ712765A (en) Antibodies that bind csf1r
NZ610734A (en) Human antibodies to the glucagon receptor
JP2015535828A5 (enExample)
NZ585559A (en) Humanized antibodies against tl1a
FI3653644T3 (fi) Monoklonaalisia vasta-aineita kasvu- ja erilaistumistekijä 15:tä (gdf-15) vastaan sekä niiden käyttöjä syöpään liittyvän kakeksian ja syövän hoitoon
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
MX341958B (es) Anticuerpos contra el il33r humano y usos de los mismos.
SI2768859T1 (en) Antagonists of il17c for the treatment of inflammatory disorders